ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results Meeting Abstract
| Authors: | Illidge, T.; Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W. S.; Feldman, T. A.; Menne, T.; Belada, D.; Illes, A.; Tobinai, K.; Tsukasaki, K.; Yeh, S. P.; Huttmann, A.; Savage, K. J.; Yuen, S.; Zinzani, P. L.; Miao, H.; Bunn, V.; Fenton, K.; Fanale, M. A.; Puhlmann, M.; Trumper, L. |
| Abstract Title: | ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results |
| Meeting Title: | 61st Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 193 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Apr 25-28 |
| Meeting Location: | Virtual |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2021-04-01 |
| Start Page: | 38 |
| End Page: | 40 |
| Language: | English |
| ACCESSION: | WOS:000645412200040 |
| PROVIDER: | wos |
| PUBMED: | 33928641 |
| DOI: | 10.1111/bjh.17490 |
| Notes: | Meeting Abstract: BSH2021-OR-039 -- Source: Wos |
